Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (35)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barrett-Connor, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrett-Connor, E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 48:345-355 (1992)
© 1992 The British Council

research-article

Harmone replacement and cancer

E Barrett-Connor

Department of Community and Family Medicine, University of California San Diego La Folla, USA

Abstract

The increasing extended use of noncontraceptive oestrogen by postmenopausal women, intended to prevent other conditions, may at the same time increase their risk of reproductive cancer. The risk of endometrial cancer triples after only a few years of unopposed oestrogen, persists for many years after oestrogen has been discontinued, and appears to be preventable by the addition of a progestin. The effect of replacement hormones on the risk of breast or ovarian cancer is unknown. Most studies suggest a small but significant increased risk of breast cancer after long-term use. Awareness of the known and uncertain cancer risks should be included in decisions to use replacement hormones.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Cell Physiol.Home page
M. E. Nuttall, G. B. Stroup, P. W. Fisher, D. P. Nadeau, M. Gowen, and L. J. Suva
Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells
Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1550 - C1557.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. E. Nuttall, J. N. Bradbeer, G. B. Stroup, D. P. Nadeau, S. J. Hoffman, H. Zhao, S. Rehm, and M. Gowen
Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats
Endocrinology, December 1, 1998; 139(12): 5224 - 5234.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M H Duncan, J C Stevenson, M Baum, W F M Posthuma, R G J Westendorp, J P Vandenbroucke, A Air, G Y H Lip, and D G Beevers
Hormone replacement therapy Cardioprotective effect is genuine
BMJ, July 16, 1994; 309(6948): 191 - 192.
[Full Text]

Home page
 Arch Intern MedHome page
M. R. Soma, I. Osnago-Gadda, R. Paoletti, R. Fumagalli, J. D. Morrisett, M. Meschia, and P. Crosignani
The Lowering of Lipoprotein[a] Induced by Estrogen Plus Progesterone Replacement Therapy in Postmenopausal Women
Arch Intern Med, June 28, 1993; 153(12): 1462 - 1468.
[Abstract] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.